CUREXIME CV Tablets combine Cefixime with Clavulanate to provide enhanced antibacterial efficacy against resistant organisms. Cefixime, a third-generation cephalosporin, inhibits bacterial cell wall synthesis, while Clavulanate acts as a beta-lactamase inhibitor, protecting Cefixime from enzymatic degradation. This combination extends the spectrum of activity and is commonly used in respiratory tract infections, urinary tract infections, ENT infections, and other bacterial conditions where resistance is a concern.
Composition
- Cefixime 200 mg
- Clavulanate 125 mg
Key Features & Benefits
- Beta-Lactamase Inhibition: Clavulanate enhances efficacy against resistant bacteria
- Extended Spectrum Coverage: Effective against a broader range of pathogens
- Dual-Action Mechanism: Combines bactericidal action with enzyme inhibition
- Ideal for Resistant Infections: Suitable where standard therapy may fail
- Widely Prescribed: Trusted in clinical practice
Recommended Usage
- To be taken as prescribed by a healthcare professional
- Preferably taken after meals to improve tolerability
- Complete the full course as advised
Safety Information
- Not recommended in patients with hypersensitivity to cephalosporins or beta-lactam antibiotics
- Use cautiously in patients with liver or kidney disorders
- May cause gastrointestinal discomfort; take with food
- Do not exceed the recommended dose
Storage Instructions
- Store in a cool, dry place
- Protect from moisture and direct sunlight
- Keep out of reach of children
